(CNBC) Gilead Sciences reported stronger-than-expected third-quarter earnings on Wednesday as sales of its coronavirus treatment remdesivir touted by President Donald Trump drove revenue up by 17% from last year. Gilead’s antiviral drug remdesivir, selling under the brand name Veklury, last week became the first and only treatment granted full approval by the U.S. Food and Drug Administration for treating Covid-19 patients.
Gilead’s revenue rises 17% driven by sales of coronavirus treatment remdesivir
This entry was posted in Syndicated. Bookmark the permalink.
